ESMO 2026 Presentations Deepen the Evidence Base for Natera’s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology
Business Wire•18/10/2026•18:10 ET
5
Key Highlights
- ➤Natera (NTRA) will present 20 abstracts, including four rapid oral presentations, at ESMO 2026
- ➤Signatera Genome achieved detection below 1 part per 10 million and an LOD95 below 1 ppm
- ➤SAGITTARIUS trial: Signatera results changed planned treatment for one in three patients
- ➤SAGITTARIUS trial: 87% of MRD-negative-driven treatment changes de-escalated therapy
- ➤ICONIC trial: Signatera detected all evaluable recurrences with over 7.3 months’ median imaging lead time
Expert Statements
Minetta Liu, Chief medical officer, oncology and early cancer detection, Natera
“We are pleased to share data at ESMO that highlights our expanding diagnostics portfolio, which includes the newest version of our ultrasensitive Signatera Genome test.”
Minetta Liu, Chief medical officer, oncology and early cancer detection, Natera
“The incorporation of phased and structural variants results in the ability to detect ctDNA significantly below 1 part per 10 million and takes MRD sensitivity into a range we haven’t seen before.”
ESMO 2026 Presentations Deepen the Evidence Base for Natera’s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology
Natera and its collaborators will present 20 abstracts, including 4 rapid oral presentations
Get started
Create a free account to read the full story.